Fangyi Zhao - Concepedia

Author

Fangyi Zhao

Eli Lilly (United States)ORCID

Also Known As

F Zhao, F. Zhao, Fang-Yi Zhao, Fangyi Zhao, Fangyi Zhao

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)University of Utah Harvard University China Medical University University of Minnesota Medical Center

About

Fangyi Zhao is an author at Eli Lilly (United States) specializing in medicine, psychiatry, and psychopharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	806
2	Social Sciences	6	6	144
3	Engineering	1	1	43
4	Public Health	1	1	28
5	Anesthesia	1	1	15

Fangyi Zhao

Publications

Citations

H-Index

Page 1

	Year	Citations
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, New England Journal of Medicine	2016	818
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, The Lancet InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseSpondyloarthritis	2018	349
Dantrolene Inhibition of Ryanodine Receptor Ca2+Release Channels Fangyi Zhao, Pin Li, S. R. Wayne Chen, Journal of Biological Chemistry	2001	321
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase <scp>III</scp> Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors Atul Deodhar, Denis Poddubnyy, César Pacheco‐Tena, Arthritis & Rheumatology	2018	224
Dose correspondence between olanzapine long-acting injection and oral olanzapine Holland C. Detke, Fangyi Zhao, Parag Garhyan, International Clinical Psychopharmacology Olanzapine Long-acting InjectionOral OlanzapinePsychiatryAddictionMedicine	2010	184
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) Maxime Dougados, James Cheng‐Chung Wei, Robert Landewé, Annals of the Rheumatic Diseases	2019	118
A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia AnnCatherine M. Downing, Bruce J. Kinon, Brian A. Millen, BMC Psychiatry	2014	113
Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells Paula Croonquist, Michael A. Linden, Fangyi Zhao, Blood	2003	82
A Dose Comparison of Olanzapine for the Treatment of Borderline Personality Disorder Mary C. Zanarini, S. Charles Schulz, Holland C. Detke, The Journal of Clinical Psychiatry	2011	81
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials Linda Stein Gold, Diamant Thaçi, Jacob P. Thyssen, American Journal of Clinical Dermatology	2023	60

Page 1